Early antiallergic inflammatory effects of Rhus verniciflua stokes on human mast cells

Phytotherapy Research

Volumn 24, Issue 2, 2010, Pages 288-294

  Hong, Myung Hee ^a   Kim, Jeong Hyun ^a   Lee, Sea Yun ^a   Go, Ho Yeon ^b   Kim, Ji Hye ^a   Shin, Yong Cheol ^a   Kim, Sung Hoon ^a   Ko, Seong Gyu ^a  

^a Kyung Hee University   (South Korea)

^b Semyung University   (South Korea)

Author keywords

Allergic inflammation; Cytokine; Human mast cells (HMC 1); MAPK; Rhus verniciflua Stokes (RVS)

Indexed keywords

ANTIALLERGIC AGENT; CALCIMYCIN; HERBACEOUS AGENT; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHORBOL 13 ACETATE 12 MYRISTATE; RHUS VERNICIFLUA STOKE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MAST CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTI-ALLERGIC AGENTS; CALCIMYCIN; CELL LINE; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; MAST CELLS; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PHOSPHORYLATION; PLANT EXTRACTS; RHUS; TETRADECANOYLPHORBOL ACETATE; TUMOR NECROSIS FACTOR-ALPHA;

TOXICODENDRON VERNICIFLUUM;

EID: 75849118035     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2941     Document Type: Article

References (38)

1. Adwanikar H, Karim F, Gereau RW 4th. 2004. Inflammation persistently enhances nocifensive behaviors mediated by spinal group I mGluRs through sustained ERK activation. Pain 111: 125-135.
2. Ashwell JD. 2006. The many paths to p38 mitogen-activated protein kinase activation in the immune system. Nat Rev Immunol 6: 532-540.
3. Baeuerle PA, Baltimore D. 1988. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 242: 540-546.
4. Baldwin AS Jr. 1996. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14: 649-683.
5. Bischoff SC. 2007. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat Rev Immunol 7: 93-104.
6. Boudreau RT, Hoskin DW, Lin TJ. 2004. Phosphatase inhibition potentiates IL-6 production by mast cells in response to FcepsilonRI-mediated activation: involvement of p38 MAPK. J Leukoc Biol 76: 1075-1081.
7. Collins T, Cybulsky MI. 2001. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 107: 255-264.
8. D'Acquisto F, Ianaro A. 2006. From willow bark to peptides: the ever widening spectrum of NF-kappaB inhibitors. Curr Opin Pharmacol 6: 387-392.
9. Feoktistov I, Goldstein AE, Biaggioni I. 1999. Role of p38 mitogen-activated protein kinase and extracellular signal-egulated protein kinase kinase in adenosine A2B receptor-mediated interleukin-8 production in human mast cells. Mol Pharmacol 55: 726-734.
10. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. 2005a. Mast cells as 'tunable' effector and immunoregulatory cells: recent advances. Annu Rev Immunol 23: 749-786.
11. Galli SJ, Nakae S, Tsai M. 2005b. Mast cells in the development of adaptive immune responses. Nat Immunol 6: 135-142.
12. Galli SJ, Tsai M, Piliponsky AM. 2008. The development of allergic inflammation. Nature 454: 445-454.
13. Hall JP, Davis RJ. 2002. Inhibition of the p38 pathway upregulates macrophage JNK and ERK activities, and the ERK, JNK, and p38 MAP kinase pathways are reprogrammed during differentiation of the murine myeloid M1 cell line. J Cell Biochem 86: 1-11.
14. Hosoda M, Yamaya M, Suzuki T et al. 2002. Effects of rhinovirus infection on histamine and cytokine production by cell lines from human mast cells and basophils. J Immunol 169: 1482-1491.
15. Javelaud D, Besancon F. 2001. NF-kappa B activation results in rapid inactivation of JNK in TNF alpha-treated Ewing sarcoma cells: a mechanism for the anti-apoptotic effect of NF-kappa B. Oncogene 20: 4365-4372.
16. Jiang S, Nakano Y, Yatsuzuka R, Ono R, Kamei C. 2007. Inhibitory effects of Moutan cortex on immediate allergic reactions. Biol Pharm Bull 30: 1707-1710.
17. Jobin C, Bradham CA, Russo MP et al. 1999. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 163: 3474-3483.
18. 2-induced cytotoxicity in macro phage RAW 264.7 cell lines. Biol Pharm Bull 29: 1603-1607.
19. Jung CH, Kim JH, Hong MH et al. 2007. Phenolic-rich fraction from Rhus verniciflua Stokes (RVS) suppress inflammatory response via NF-kappaB and JNK pathway in lipopolysaccharide-induced RAW 264.7 macrophages. J Ethnopharmacol 110: 490-497.
20. Kaminska B. 2005. MAPK signalling pathways as molecular targets for anti-inflammatory therapy - from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 1754: 253-262.
21. Karin M, Ben-Neriah Y. 2000. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18: 621-663.
22. Kempuraj D, Huang M, Kandere K et al. 2002. Azelastine is more potent than olopatadine in inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells. Ann Allergy Asthma Immunol 88: 501-506.
23. Kim JH, Kim HP, Jung CH et al. 2006. Inhibition of cell cycle progression via p27Kip1 upregulation and apoptosis induction by an ethanol extract of Rhus verniciflua Stokes in AGS gastric cancer cells. Int J Mol Med 18: 201-208.
24. Kim SH, Kim SA, Park MK et al. 2004. Paeonol inhibits anaphylactic reaction by regulating histamine and TNF-alpha. Int Immunopharmacol 4: 279-287.
25. Kim TJ. 1996. Korean Resource Plant (Volume II). Seoul University Press: Seoul, 292-297.
26. Kyriakis JM, Avruch J. 1996. Sounding the alarm: protein kinase cascades activated by stress and inflammation. J Biol Chem 271: 24313-24316.
27. Lee JC, Lim KT, Jang YS. 2002. Identification of Rhus verniciflua Stokes compounds that exhibit free radical scavenging and anti-apoptotic properties. Biochim Biophys Acta 1570: 181-191.
28. Lim KT, Hu C, Kitts DD. 2001. Antioxidant activity of a Rhus verniciflua Stokes ethanol extract. Food Chem Toxicol 39: 229-237.
29. Lippert U, Moller A, Welker P, Artuc M, Henz BM. 2000. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol 9: 118-124.
30. Schroecksnadel K, Winkler C, Wirleitner B, Schennach H, Weiss G, Fuchs D. 2005. Anti-inflammatory compound resveratrol suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells in vitro. Clin Chem Lab Med 43: 1084-1088.
31. Shapiro L, Dinarello CA. 1997. Hyperosmotic stress as a stimulant for proinflammatory cytokine production. Exp Cell Res 231: 354-362.
32. Simmonds RE, Foxwell BM. 2008. Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammation. Rheumatology (Oxford) 47: 584-590.
33. Strik MC, de Koning PJ, Kleijmeer MJ et al. 2007. Human mast cells produce and release the cytotoxic lymphocyte associated protease granzyme B upon activation. Mol Immunol 44: 3462-3472.
34. Tang G, Minemoto Y, Dibling B et al. 2001. Inhibition of JNK activation through NF-kappaB target genes. Nature 414: 313-317.
35. Thomas PS. 2001. Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma. Immunol Cell Biol 79: 132-140.
36. Wong CK, Tsang CM, Ip WK, Lam CW. 2006. Molecular mechanisms for the release of chemokines from human leukemic mast cell line (HMC)-1 cells activated by SCF and TNF-alpha: roles of ERK, p38 MAPK, and NF-kappaB. Allergy 61: 289-297.
37. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB. 1999. Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 274: 27307-27314.
38. Zu YL, Qi J, Gilchrist A et al. 1998. p38 mitogen-activated protein kinase activation is required for human neutrophil function triggered by TNF-alpha or FMLP stimulation. J Immunol 160: 1982-1989.